CL2020001047A1 - Derivados de imidazol condensado sustituidos por grupos de hidroxia terciaria como inhibidores pi3k-gamma. - Google Patents

Derivados de imidazol condensado sustituidos por grupos de hidroxia terciaria como inhibidores pi3k-gamma.

Info

Publication number
CL2020001047A1
CL2020001047A1 CL2020001047A CL2020001047A CL2020001047A1 CL 2020001047 A1 CL2020001047 A1 CL 2020001047A1 CL 2020001047 A CL2020001047 A CL 2020001047A CL 2020001047 A CL2020001047 A CL 2020001047A CL 2020001047 A1 CL2020001047 A1 CL 2020001047A1
Authority
CL
Chile
Prior art keywords
pi3k
hydroxy groups
imidazole derivatives
derivatives substituted
fused imidazole
Prior art date
Application number
CL2020001047A
Other languages
English (en)
Inventor
David M Burns
Nikoo Falahatpisheh
Brent Douty
Andrew W Buesking
Andrew P Combs
Ravi Kumar Jalluri
Daniel Levy
Padmaja Polam
Lixin Shao
Stacey Shepard
Artem Shvartsbart
Richard B Sparks
Eddy W Yue
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of CL2020001047A1 publication Critical patent/CL2020001047A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A COMPUESTOS DE FÓRMULA (I), O SALES DE LOS MISMOS FARMACÉUTICAMENTE ACEPTABLES, LOS CUALES SON INHIBIDORES DE PI3K-Γ LOS CUALES SON ÚTILES PARA EL TRATAMIENTO DE TRASTORNOS TALES COMO ENFERMEDADES AUTOINMUNES, CÁNCER, ENFERMEDADES CARDIOVASCULARES, Y ENFERMEDADES NEURODEGENERATIVAS.
CL2020001047A 2017-10-18 2020-04-17 Derivados de imidazol condensado sustituidos por grupos de hidroxia terciaria como inhibidores pi3k-gamma. CL2020001047A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762574057P 2017-10-18 2017-10-18
US201762608897P 2017-12-21 2017-12-21
US201862727316P 2018-09-05 2018-09-05

Publications (1)

Publication Number Publication Date
CL2020001047A1 true CL2020001047A1 (es) 2020-08-28

Family

ID=64110207

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020001047A CL2020001047A1 (es) 2017-10-18 2020-04-17 Derivados de imidazol condensado sustituidos por grupos de hidroxia terciaria como inhibidores pi3k-gamma.

Country Status (33)

Country Link
US (4) US10738057B2 (es)
EP (2) EP3697789B1 (es)
JP (2) JP7244504B2 (es)
CN (2) CN111542526B (es)
AU (2) AU2018350980B2 (es)
BR (1) BR112020007593A2 (es)
CA (1) CA3084589A1 (es)
CL (1) CL2020001047A1 (es)
CR (2) CR20200214A (es)
CY (1) CY1124814T1 (es)
EC (1) ECSP20024651A (es)
ES (1) ES2902390T3 (es)
GE (1) GEP20237483B (es)
HR (1) HRP20211827T1 (es)
HU (1) HUE056615T2 (es)
IL (3) IL295978B2 (es)
JO (1) JOP20200086A1 (es)
LT (1) LT3697789T (es)
MA (1) MA50398B1 (es)
MD (1) MD3697789T2 (es)
MX (1) MX2020003862A (es)
PE (1) PE20210169A1 (es)
PH (1) PH12020550442A1 (es)
PL (1) PL3697789T3 (es)
PT (1) PT3697789T (es)
RS (1) RS62818B1 (es)
SA (1) SA520411783B1 (es)
SG (1) SG11202003428VA (es)
SI (1) SI3697789T1 (es)
TW (2) TWI834560B (es)
UA (1) UA128085C2 (es)
WO (1) WO2019079469A1 (es)
ZA (1) ZA202201220B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11926630B2 (en) 2017-10-18 2024-03-12 Incyte Corporation Tertiary alcohols as PI3K-γ inhibitors

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020006490A (es) 2017-12-19 2020-08-17 Turning Point Therapeutics Inc Compuestos macrociclicos para tratar enfermedades.
SI3762368T1 (sl) 2018-03-08 2022-06-30 Incyte Corporation Aminopirazin diolne spojine kot zaviralci PI3K-y
CN113166153A (zh) 2018-07-05 2021-07-23 因赛特公司 作为a2a/a2b抑制剂的稠合吡嗪衍生物
JP2021535182A (ja) 2018-09-05 2021-12-16 インサイト・コーポレイションIncyte Corporation ホスホイノシチド３−キナーゼ（ｐｉ３ｋ）阻害剤の結晶形態
CN115286521B (zh) * 2022-07-11 2023-11-03 上海医药集团(本溪)北方药业有限公司 一种盐酸左沙丁胺醇的合成方法

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4269846A (en) 1979-10-29 1981-05-26 Usv Pharmaceutical Corporation Heterocyclic compounds useful as anti-allergy agents
US5137876A (en) 1990-10-12 1992-08-11 Merck & Co., Inc. Nucleoside antiviral and anti-inflammatory compounds and compositions and methods for using same
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
BR9912938B1 (pt) 1998-08-11 2011-06-28 derivados de isoquinolina, composição que os compreende, processo para preparação e uso dos mesmos.
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0011092D0 (en) 2000-05-08 2000-06-28 Black James Foundation Gastrin and cholecystokinin receptor ligands (III)
CZ303572B6 (cs) 2000-06-28 2012-12-12 Smithkline Beecham P. L. C. Jemne rozmelnený prostredek a zpusob jeho prípravy
CN100391958C (zh) 2001-09-19 2008-06-04 安万特医药股份有限公司 化合物
FR2831536A1 (fr) 2001-10-26 2003-05-02 Aventis Pharma Sa Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr
AU2002334217B2 (en) 2001-10-26 2008-07-03 Aventis Pharmaceuticals Inc. Benzimidazoles and analogues and their use as protein kinases inhibitors
CA2462657C (en) 2001-10-30 2011-04-26 Novartis Ag Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
DE10207843A1 (de) 2002-02-15 2003-09-04 Schering Ag Mikrolia-Inhibitoren zur Unterbrechung von Interleukin 12 und IFN-gamma vermittelten Immunreaktionen
AR037647A1 (es) 2002-05-29 2004-12-01 Novartis Ag Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
CL2003002353A1 (es) 2002-11-15 2005-02-04 Vertex Pharma Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US7157460B2 (en) 2003-02-20 2007-01-02 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
US7186832B2 (en) * 2003-02-20 2007-03-06 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
WO2004078943A2 (en) 2003-03-04 2004-09-16 California Institute Of Technology Alternative heterocycles for dna recognition
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
AU2004261667A1 (en) 2003-08-01 2005-02-10 Genelabs Technologies, Inc. Bicyclic imidazol derivatives against Flaviviridae
AR045944A1 (es) 2003-09-24 2005-11-16 Novartis Ag Derivados de isoquinolina 1.4-disustituidas
WO2005037836A2 (en) * 2003-10-15 2005-04-28 Osi Pharmaceuticals, Inc. Imidazo ‘1, 5 - a ! pyrazine tyrosine kinase inhibitors
WO2005118580A2 (en) 2004-05-12 2005-12-15 The Government Of The United States Of America As Represented By The Secretary, Department Of Health Tricyclic compounds as inhibitors of the hypoxic signaling pathway
RU2401265C2 (ru) 2004-06-10 2010-10-10 Айрм Ллк Соединения и композиции в качестве ингибиторов протеинкиназы
US20090156602A1 (en) 2004-11-24 2009-06-18 Nigel Graham Cooke Organic Compounds
DK1910384T3 (da) 2005-08-04 2012-12-17 Sirtris Pharmaceuticals Inc Imidazo [2,1-b] thiazol-derivater som sirtuinmodulerende forbindelser
WO2007028051A2 (en) 2005-09-02 2007-03-08 Abbott Laboratories Novel imidazo based heterocycles
JP2009541268A (ja) 2006-06-22 2009-11-26 ビオヴィトルム・アクチボラゲット（プブリクト） Ｍｎｋキナーゼ阻害剤としてのピリジンおよびピラジン誘導体
WO2009005551A2 (en) 2007-03-27 2009-01-08 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
DE102007035333A1 (de) 2007-07-27 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
GB0716292D0 (en) 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
MY152948A (en) 2007-11-16 2014-12-15 Incyte Corp 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
WO2009079011A1 (en) 2007-12-19 2009-06-25 The Scripps Research Institute Benzimidazoles and analogs as rho kinase inhibitors
CN101990434B (zh) 2008-01-15 2013-07-31 西佳技术公司 用于治疗沙粒病毒感染的抗病毒药物
ATE555116T1 (de) 2008-02-26 2012-05-15 Merck Sharp & Dohme Ahcy-hydrolasehemmer zur behandlung von hyperhomocysteinämie
JP5275371B2 (ja) 2008-03-11 2013-08-28 インサイト・コーポレイション Ｊａｋ阻害剤としてのアゼチジン誘導体およびシクロブタン誘導体
WO2009133127A1 (en) 2008-04-30 2009-11-05 Merck Serono S.A. Fused bicyclic compounds and use thereof as pi3k inhibitors
US8362268B2 (en) 2008-05-30 2013-01-29 University Of Notre Dame Du Lac Anti-bacterial agents from benzo[d]heterocyclic scaffolds for prevention and treatment of multidrug resistant bacteria
US8470819B2 (en) 2008-11-03 2013-06-25 Merck Sharp & Dohme Corp. Benzimidazole and aza-benzimidazole carboxamides
WO2010061903A1 (ja) 2008-11-27 2010-06-03 塩野義製薬株式会社 Pi3k阻害活性を有するピリミジン誘導体およびピリジン誘導体
GB0822981D0 (en) 2008-12-17 2009-01-21 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
WO2010135014A1 (en) 2009-02-27 2010-11-25 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
ES2475091T3 (es) * 2009-04-16 2014-07-10 Centro Nacional De Investigaciones Oncol�Gicas (Cnio) Imidazopirazinas como inhibidores de proteína cinasas
BRPI1012159B1 (pt) 2009-05-22 2022-01-25 Incyte Holdings Corporation Compostos derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d] pirimidinas e pirrol-3-il-pirrolo[2,3-d] pirimidinas como inibidores de janus cinase, composições farmacêuticas compreendendo os referidos compostos e usos dos mesmos
SI2448938T1 (sl) 2009-06-29 2014-08-29 Incyte Corporation Experimental Station Pirimidinoni kot zaviralci pi3k
AR078012A1 (es) 2009-09-01 2011-10-05 Incyte Corp Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
TW201130842A (en) 2009-12-18 2011-09-16 Incyte Corp Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors
WO2011099832A2 (en) 2010-02-12 2011-08-18 Crystalgenomics, Inc. Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
AU2011224484A1 (en) 2010-03-10 2012-09-27 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
US20130018039A1 (en) 2010-03-31 2013-01-17 Bodmer Vera Q Imidazolyl-imidazoles as kinase inhibitors
US9193721B2 (en) 2010-04-14 2015-11-24 Incyte Holdings Corporation Fused derivatives as PI3Kδ inhibitors
CA2800509A1 (en) 2010-05-24 2011-12-01 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
EP2627650A2 (en) 2010-05-26 2013-08-21 Merck Sharp & Dohme Corp. N-phenyl imidazole carboxamide inhibitors of 3-phosphoinositide-dependent protein kinase-1
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
KR20140091462A (ko) 2010-10-13 2014-07-21 밀레니엄 파머슈티컬스 인코퍼레이티드 헤테로아릴 및 그의 용도
ES2536415T3 (es) 2010-11-19 2015-05-25 Incyte Corporation Pirrolopiridinas y pirrolopirimidinas sustituidas heterocíclicas como inhibidores de JAK
PE20140146A1 (es) 2010-11-19 2014-02-06 Incyte Corp Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
SG190925A1 (en) 2010-11-30 2013-07-31 Takeda Pharmaceutical Bicyclic compound
ES2764848T3 (es) 2010-12-20 2020-06-04 Incyte Holdings Corp N-(1-(fenilo sustituido)etilo)-9H-purina-6-aminas como inhibidores de PI3K
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
US8673905B2 (en) 2011-03-17 2014-03-18 Hoffmann-La Roche Inc. Imidazo pyrazines
WO2012135009A1 (en) 2011-03-25 2012-10-04 Incyte Corporation Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
US9029389B2 (en) 2011-04-21 2015-05-12 Institut Pasteur Korea Anti-inflammation compounds
EP2718279B1 (en) 2011-06-09 2016-08-10 Rhizen Pharmaceuticals SA Novel compounds as modulators of gpr-119
AR086983A1 (es) 2011-06-20 2014-02-05 Incyte Corp Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
HUE030869T2 (en) 2011-09-02 2017-06-28 Incyte Holdings Corp Heterocyclic amines as inhibitors of PI3K
CN104066735B (zh) 2012-01-10 2016-08-31 拜耳知识产权有限责任公司 作为akt激酶抑制剂的取代的咪唑并吡嗪
US9212169B2 (en) 2012-03-01 2015-12-15 Hyogo College Of Medicine Benzimidazole derivative and use thereof
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
WO2013173720A1 (en) 2012-05-18 2013-11-21 Incyte Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
WO2013180193A1 (ja) 2012-05-31 2013-12-05 住友化学株式会社 縮合複素環化合物
EA028722B1 (ru) 2012-07-13 2017-12-29 Юсб Байофарма Спрл Производные имидазопиридина в качестве модуляторов активности tnf
MX2015005428A (es) 2012-11-01 2015-07-21 Incyte Corp Derivados triciclicos fusionados de tiofeno como inhibidores de la cinasa janus (jak).
TW202214254A (zh) 2013-03-01 2022-04-16 美商英塞特控股公司 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途
WO2014149207A2 (en) 2013-03-15 2014-09-25 Dow Agrosciences Llc Benzimidazole-based insecticidal compositions and related methods
US8999992B2 (en) 2013-03-15 2015-04-07 Vm Pharma Llc Crystalline forms of tryosine kinase inhibitors and their salts
EP2976077A4 (en) 2013-03-22 2016-11-30 Scripps Research Inst BENZIMIDAZOLES SUBSTITUTED AS MODULATORS OF A NOCICEPTIN RECEPTOR
EP2994142A4 (en) 2013-05-08 2017-03-29 Colorado Seminary, Which Owns and Operates The University of Denver Antibiotic and anti-parasitic agents that modulate class ii fructose 1,6-bisphosphate aldolase
TWI719401B (zh) 2013-05-17 2021-02-21 美商英塞特公司 作為jak抑制劑之聯吡唑衍生物
TWI641595B (zh) 2013-07-17 2018-11-21 日商大塚製藥股份有限公司 氰基三唑化合物類
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PL3129021T3 (pl) 2014-04-08 2021-05-31 Incyte Corporation Leczenie nowotworów złośliwych z komórek b za pomocą skojarzenia inhibitora jak i pi3k
EP2930048A1 (en) 2014-04-10 2015-10-14 Johnson Controls Automotive Electronics SAS Head up display projecting visual information onto a screen
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
MX2017003464A (es) 2014-09-16 2017-07-13 Celgene Quanticel Res Inc Inhibidores de histona desmetilasa.
ES2749679T3 (es) * 2014-10-22 2020-03-23 Bristol Myers Squibb Co Compuestos de pirrolotriazina amina sustituidos como inhibidores de PI3k
EP3209664B1 (en) * 2014-10-22 2020-06-03 Bristol-Myers Squibb Company Bicyclic heteroaryl amine compounds as pi3k inhibitors
MA40933A (fr) 2014-11-11 2017-09-19 Piqur Therapeutics Ag Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines
WO2016106624A1 (en) * 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Tertiary alcohol imidazopyrazine btk inhibitors
WO2016130501A1 (en) 2015-02-09 2016-08-18 Incyte Corporation Aza-heteroaryl compounds as pi3k-gamma inhibitors
US9968604B2 (en) * 2015-04-16 2018-05-15 Chiesi Farmaceutici S.P.A. Chromene derivatives as phoshoinositide 3-kinases inhibitors
AU2016261730A1 (en) 2015-05-12 2017-11-16 Zeno Royalties & Milestones, LLC Bicyclic compounds
MA43169B1 (fr) 2015-11-06 2022-05-31 Incyte Corp Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma
EP3400221B1 (en) 2016-01-05 2020-08-26 Incyte Corporation Pyrazol / imidazol substituted pyridines as pi3k-gamma inhibitors
TW201803871A (zh) 2016-06-24 2018-02-01 英塞特公司 作為ＰＩ３Ｋ-γ抑制劑之雜環化合物
RU2019108464A (ru) 2016-08-26 2020-09-28 Мицубиси Танабе Фарма Корпорейшн Бициклическое азотсодержащее гетероциклическое соединение
WO2018136754A1 (en) 2017-01-20 2018-07-26 Massachusetts Institute Of Technology Injectable polymer micro-depots for controlled local drug delivery
TWI674261B (zh) 2017-02-17 2019-10-11 美商英能腫瘤免疫股份有限公司 Nlrp3 調節劑
SG11201912166XA (en) 2017-07-24 2020-02-27 Novartis Inflammasome Research Inc Compounds and compositions for treating conditions associated with nlrp activity
US10988454B2 (en) 2017-09-14 2021-04-27 Abbvie Overseas S.À.R.L. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
WO2019079469A1 (en) 2017-10-18 2019-04-25 Incyte Corporation CONDENSED IMIDAZOLE DERIVATIVES SUBSTITUTED WITH HYDROXY TERTIARY GROUPS AS INHIBITORS OF PI3K-GAMMA
WO2019079540A1 (en) 2017-10-18 2019-04-25 Epizyme, Inc. AMINO-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS INHIBITORS OF EHMT2, SALTS THEREOF, AND METHODS OF SYNTHESIS THEREOF
MX2020006490A (es) 2017-12-19 2020-08-17 Turning Point Therapeutics Inc Compuestos macrociclicos para tratar enfermedades.
CN111491925B (zh) 2017-12-21 2023-12-29 巴斯夫欧洲公司 杀害虫化合物
SG11202005881YA (en) 2017-12-21 2020-07-29 Boehringer Ingelheim Int Novel benzylamino substituted pyridopyrimidinones and derivatives as sos1 inhibitors
JP2021535182A (ja) 2018-09-05 2021-12-16 インサイト・コーポレイションIncyte Corporation ホスホイノシチド３−キナーゼ（ｐｉ３ｋ）阻害剤の結晶形態

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11926630B2 (en) 2017-10-18 2024-03-12 Incyte Corporation Tertiary alcohols as PI3K-γ inhibitors

Also Published As

Publication number Publication date
EP3697789A1 (en) 2020-08-26
ZA202201220B (en) 2023-03-29
KR20200089264A (ko) 2020-07-24
CR20210442A (es) 2021-12-20
ES2902390T3 (es) 2022-03-28
IL295978B2 (en) 2024-01-01
UA128085C2 (uk) 2024-04-03
RS62818B1 (sr) 2022-02-28
US20220213107A1 (en) 2022-07-07
MA50398B1 (fr) 2021-10-29
CY1124814T1 (el) 2022-11-25
SG11202003428VA (en) 2020-05-28
JP7244504B2 (ja) 2023-03-22
SI3697789T1 (sl) 2022-04-29
CN118063470A (zh) 2024-05-24
PL3697789T3 (pl) 2022-02-21
ECSP20024651A (es) 2020-06-30
SA520411783B1 (ar) 2024-05-12
AU2018350980B2 (en) 2023-02-23
EP3697789B1 (en) 2021-09-29
CA3084589A1 (en) 2019-04-25
US10738057B2 (en) 2020-08-11
MX2020003862A (es) 2020-08-13
IL295978A (en) 2022-10-01
IL273983B2 (en) 2023-02-01
LT3697789T (lt) 2021-12-10
TWI803525B (zh) 2023-06-01
JP7541594B2 (ja) 2024-08-28
BR112020007593A2 (pt) 2020-09-24
CR20200214A (es) 2020-07-25
AU2023203088B2 (en) 2024-10-03
HRP20211827T1 (hr) 2022-03-18
MA50398A (fr) 2021-05-05
MD3697789T2 (ro) 2022-02-28
PH12020550442A1 (en) 2021-05-31
US20240228498A1 (en) 2024-07-11
US20200385392A1 (en) 2020-12-10
US11225486B2 (en) 2022-01-18
US11926630B2 (en) 2024-03-12
TWI834560B (zh) 2024-03-01
PE20210169A1 (es) 2021-01-29
TW202340200A (zh) 2023-10-16
JP2021500340A (ja) 2021-01-07
IL295978B1 (en) 2023-09-01
JP2023085290A (ja) 2023-06-20
AU2018350980A1 (en) 2020-04-30
CN111542526B (zh) 2024-01-09
AU2023203088A1 (en) 2023-06-15
US20190152975A1 (en) 2019-05-23
HUE056615T2 (hu) 2022-02-28
IL273983A (en) 2020-05-31
IL273983B (en) 2022-10-01
JOP20200086A1 (ar) 2020-04-30
GEP20237483B (en) 2023-03-27
TW201927788A (zh) 2019-07-16
PT3697789T (pt) 2021-12-31
CN111542526A (zh) 2020-08-14
EP4006034A1 (en) 2022-06-01
WO2019079469A1 (en) 2019-04-25

Similar Documents

Publication Publication Date Title
CL2020001047A1 (es) Derivados de imidazol condensado sustituidos por grupos de hidroxia terciaria como inhibidores pi3k-gamma.
CL2020001547A1 (es) Carbamoíl ciclohexil ácidos ligados a n de triazol como antagonistas de lpa.
ECSP20060827A (es) Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b
UY37302A (es) Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
ECSP24026455A (es) Compuestos de pirrolotriazina como inhibidores de tam
CU20160167A7 (es) Compuestos de pirazolopiridinas y pirazolopirimidinas útiles en el tratamiento de condiciones alérgicas y respiratorias
ECSP17073191A (es) Compuestos heterocíclicos como inhibidores de lsd1
DOP2015000158A (es) Inhibidores de prmt5 y sus usos
CU20160188A7 (es) Compuestos de indazole substituidos como inhibidores de irak4
EA201890308A1 (ru) Замещенные азасоединения как ингибиторы irak-4
CL2020001576A1 (es) Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5.
CO2018001268A2 (es) Derivados de heteroarilo como inhibidores de parp
UY36244A (es) Derivados de la pirimidinona como inhibidores del factor xia y/o de la calicreína plasmática y composiciones farmacéuticas que los contienen
UY37900A (es) Nuevos derivados de rapamicina
ECSP17021897A (es) Compuestos y composiciones como inhibidores de quinasa raf
UY36170A (es) Compuestos de dihidroisoquinolinona sustituida
GT201300174A (es) Compuestos de indol o análogos de los mismos útiles para el tratamiento de la degeneración macular relacionada con la edad (dme)
CU20160192A7 (es) Derivados de indano e indolina útiles como activadores de la guanilato ciclasa soluble
UY35273A (es) Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con defici encia de smn
ECSP20061378A (es) COMPUESTOS DIÓLICOS DE AMINOPIRAZINA COMO INHIBIDORES DE PI3K-gamma
CO7280468A2 (es) Antagonistas del receptor de 5-ht3
BR112016024936A2 (pt) moduladores de gpr40 à base de pirrolidina para tratamento de doenças como diabetes
CL2022000457A1 (es) Triazolopirimidinas como inhibidores de a2a/a2b.
CO2017000011A2 (es) Derivados de quinolizinona como inhibidores de pi3k
CO2020010042A2 (es) Compuestos de alquinileno sustituidos como agentes anticancerígenos